Trial Profile
Dipeptide Alanyl Glutamine Prevents Postoperative Insulin Resistance in Colon Carcinoma Patients.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 09 Oct 2013
Price :
$35
*
At a glance
- Drugs Alanylglutamine (Primary)
- Indications Insulin resistance
- Focus Therapeutic Use
- Acronyms AIRCo
- 08 Aug 2011 New trial record